Background. Peginterferon lambda-1a (Lambda, Type III IFN) is currently under Phase 3 evaluation as part of combination treatment for HCV infection. The triple regimen of Lambda, daclatasvir (DCV; NS5A inhibitor) and ribavirin (RBV) achieved sustained virologic response (SVR) rates of >90% in a pilot study of patients chronically infected with genotype 1b HCV when treated for 24 weeks. This triple combination regimen was evaluated for 12 weeks of treatment in a cohort of patients with genotype 1b infection (Study AI452-008c).
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Methods. 24 treatment-naive, non-cirrhotic HCV genotype 1b infected patients were treated with open-label Lambda 180 mcg/week + DCV 60mg daily + RBV 1,000-1,200 mg daily for 12 weeks. The primary endpoint is HCV RNA <LLOQ (25 IU/mL) at 12 weeks post-treatment (SVR12). SVR4 results are reported here with SVR12 available at presentation.
Results. Baseline characteristics were male 46%, Caucasian 96%, and IL28B non-CC genotype 67%. Mean baseline HCV RNA was 6.3 (range 5.1-7.4) log10 IU/mL. SVR4 was achieved in 21/23 (91%) patients with available data. Both patients who did not achieve SVR4 experienced relapse posttreatment. No patients discontinued treatment due to AEs or treatment futility; there were no deaths and no serious AEs. The most frequent AEs were asthenia, pruritus, dry skin and diarrhea. One patient each (n = 3/24) had a Grade 3/4 lab abnormality of elevated ALT/AST, reduced hemoglobin, or increased bilirubin.
Observed mITT HCV RNA <LLOQ at end of treatment, n/N (%) 24/24 (100) 24/24 (100) SVR4, n/N (%) 21/23 (91)* 21/24 (88) Post-treatment relapse (n) 2 *1 patient was lost to follow-up (Week 8 undetectable), counted as failure for mITT analysis
Conclusion. 12 weeks of treatment with Lambda + DCV + RBV achieved a high SVR4 rate in treatment-naïve, non-cirrhotic HCV genotype 1b-infected patients. The regimen was generally well tolerated.
Disclosures. M. Brunetto, AbbVie, BMS, Gilead, Janssen, MSD, Roche, Novartis: Speaker's Bureau, Speaker honorarium K. Rana, Bristol-Myers Squibb: Employee, Salary E. Lawitz, AbbVie, Achillion Pharmaceuticals, BioCryst, Biotica, Enanta, Idenix Pharmaceuticals, Janssen, Merck: Scientific Advisor, Consulting fee; AbbVie, Achillion Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Idenix Pharmaceuticals: Grant Investigator, Grant recipient and Research support; Gilead, Kadmon, Merck, Vertex: Speaking and Teaching, Speaker honorarium C. Hézode, Abbvie, BMS, Gilead, Janssen, MSD, Roche: Consultant, Personal fee P. Marcellin, Roche: Consultant, Grant Investigator and Speaker, Consulting fee, Grant recipient and Speaker honorarium; Gilead: Consultant, Grant Investigator and Speaker, Consulting fee, Grant recipient and Speaker honorarium; Bristol-Myers Squibb: Consultant, Grant Investigator and Speaker, Consulting fee, Grant recipient and Speaker honorarium; Vertex: Consultant and Investigator, Consulting fee; Novartis: Consultant, Grant Investigator and Speaker, Consulting fee, Grant recipient and Speaker honorarium; Janssen-Tibotec: Consultant, Grant Investigator and Speaker, Consulting fee, Grant recipient and Speaker honorarium; MSD: Consultant, Grant Investigator and Speaker, Consulting fee, Grant recipient and Speaker honorarium; Boehringer: Investigator, Consulting fee; Abbott: Consultant and Investigator, Consulting fee; Pfizer: Investigator, Consulting fee; Alios BioPharma: Grant Investigator, Grant recipient D. Cohen, Bristol-Myers Squibb: Employee, Salary S. Srinivasan, Bristol-Myers Squibb: Employee, Salary
